Quarterly ResultMay 11, 2026, 04:16 PM
Gain Therapeutics Q1 Net Loss $5.6M; Going Concern Doubt
AI Summary
Gain Therapeutics reported a significant increase in net loss for Q1 2026, reaching $5.61 million, up from $4.53 million in the prior year. The company also disclosed substantial doubt about its ability to continue as a going concern beyond the first quarter of 2027, citing insufficient cash to fund operations. Operating expenses, including R&D and G&A, rose, while cash used in operating activities increased to $4.73 million.
Key Highlights
- Substantial doubt about ability to continue as a going concern beyond Q1 2027.
- Q1 2026 net loss increased to $5.61 million from $4.53 million in Q1 2025.
- Net loss per share was $(0.13) in Q1 2026, compared to $(0.16) in Q1 2025.
- Cash and cash equivalents were $16.54 million as of March 31, 2026.
- Cash used in operating activities rose to $4.73 million in Q1 2026.
- Research and development expenses increased to $2.76 million in Q1 2026.
- General and administrative expenses rose to $2.59 million in Q1 2026.
- Net proceeds from ATM offering were $0.43 million in Q1 2026.
Price Impact
More from GANX